A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Breast cancer; Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 12 Sep 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 11 Sep 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
- 11 Sep 2013 Planned End Date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.